Down-regulation of HLA-I and APM components during the malignant process of cervical cancer.

<p>Analyze the clinicopathologic characteristics (tumor grad, clinical stage and Lymph node metastases) with protein expression of HLA-I and APM components (TAP-1, TAP-2, LMP2, LMP7, Tapasin, ERAP1, CNX, CRT and ERp57) in cervical cancer.Results are represented as percentage (%). upper histogram A1 show HLA-I and APM components expressed in well differentiated tumor, A2 show expressed in Moderate to poorly differentiated tumor. B1 show expressed in ≤II a tumor and B2 show expressed in ≥II B, C1 show expressed in Lymph node metastases negative tumor and C2 show expressed in Lymph node metastases positive tumor, respectively. * <i>P</i> < 0.05.